(September 18, 2017, 12:10 PM EDT) -- SAN FRANCISCO — The Ninth Circuit U.S. Court of Appeals on Sept. 15 told parties in the incretin mimetics multidistrict litigation appeal that it wants them to address the effect of the Third Circuit’s warnings ruling in the Fosamax femur fracture multidistrict litigation when their case comes up for argument on Oct. 3 (In Re: Incretin-Based Therapies Products Liability Litigation, Jean Adams, et al. v. Merck Sharp & Dohme Corp., et al., No. 15-56997, 9th Cir.)....